摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5.6-Bis--pyrido<2'.3':2.3>-pyrazin | 17601-28-4

中文名称
——
中文别名
——
英文名称
5.6-Bis--pyrido<2'.3':2.3>-pyrazin
英文别名
2,3-di(2-pyridyl)pyrido[2,3-b]pyrazine;2,3-dipyridin-2-yl-pyrido[2,3-b]pyrazine;2,3-dipyridyl-1,4,8-triazanaphthalene;2,3-dipyridin-2-ylpyrido[2,3-b]pyrazine
5.6-Bis-<pyridyl-(2)>-pyrido<2'.3':2.3>-pyrazin化学式
CAS
17601-28-4
化学式
C17H11N5
mdl
——
分子量
285.308
InChiKey
NTRLDSRCNOIEMV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    22
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    64.4
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    五羰基氯铼(I)5.6-Bis--pyrido<2'.3':2.3>-pyrazin甲醇 为溶剂, 生成 [Re(CO)3Cl]2(2,3-di(2-pyridyl)pyrido[2,3-b]pyrazine)
    参考文献:
    名称:
    Spectroscopic and Electrochemical Studies of Rhenium(I) Bimetallic Complexes with Asymmetric Polypyridyl Bridging Ligands
    摘要:
    The synthesis and electrochemical and spectroscopic properties of a number of binuclear rhenium(I) ligand-bridged complexes are reported. The ligands are as follows: 2,3 -di(2-pyridyl)quinoxaline; 2,3-di(2-pyridyl)-6-methyl quinoxaline; 2,3-di(2-pyridyl)pyrido[2,3-b]pyrazine; 2,3-di(2-pyridyl)pyrido[3,3-b]pyrazine. Complexes with these ligands show different electrochemical and spectroscopic properties. The pyridopyrazine ring systems show longer wavelength MLCT transitions and are easier to reduce. However, spectroelectrochemical studies reveal that the reduction products for this series of complexes are spectroscopically similar. Raman measurements on the reduced species suggest that the redox orbital for the first reduction resides in an orbital that is localized at the dipyridyl section of each ligand. This is surprising in view of the fact that the larger ring system would be expected to localize the charge. It suggests that the rhenium centers modify the nature of the redox MO to a greater extent than the pyridopyrazine ring system.
    DOI:
    10.1021/ic00129a018
  • 作为产物:
    描述:
    2,3-二氨基吡啶二(2-吡啶基)乙二酮甲醇溶剂黄146 为溶剂, 反应 0.08h, 以94%的产率得到5.6-Bis--pyrido<2'.3':2.3>-pyrazin
    参考文献:
    名称:
    方便合成喹喔啉和杂环吡嗪的通用微波辅助方案
    摘要:
    方便地在微波辐射下,从常见的1,2-二酮中间体以优异的收率(69–99%)制备功能化的喹喔啉和杂环吡嗪。除了可以广泛用于各种芳基/杂芳基1,2-二胺和1,2-二酮外,该方案还可以抑制传统热条件下的聚合物种类的形成。
    DOI:
    10.1016/j.tetlet.2004.04.144
点击查看最新优质反应信息

文献信息

  • Microwave-assisted Solvent-free Synthesis and in Vitro Antibacterial Screening of Quinoxalines and Pyrido[2, 3b]pyrazines
    作者:J. Jesús Morales-Castellanos、Karina Ramírez-Hernández、Nancy S. Gómez-Flores、Oscar R. Rodas-Suárez、Javier Peralta-Cruz
    DOI:10.3390/molecules17055164
    日期:——
    We report herein the microwave assisted synthesis, without solvents and catalysts, of 6-substituted quinoxalines and 7-substituted pyrido[2,3b]pyrazines. The compounds were obtained in good yields and short reaction times using the mentioned procedure and two new structures are reported. A complete 1H- and 13C-NMR assignment was performed using 1D and 2D-NMR. Additionally, an in vitro screening was
    我们在此报告了 6-取代喹喔啉和 7-取代吡啶并 [2,3b] 吡嗪的微波辅助合成,无需溶剂和催化剂。使用上述程序以良好的收率和较短的反应时间获得了化合物,并报告了两种新结构。使用 1D 和 2D-​​NMR 进行了完整的 1H-和 13C-NMR 分配。此外,使用阿莫西林作为阳性参照对革兰氏阳性菌和革兰氏阴性菌进行了体外筛选。带有吡啶基的化合物往往具有较高的抗菌活性,但喹喔啉衍生物对枯草芽孢杆菌和奇异变形杆菌的抗菌活性最好。
  • Imidazolium cations, processes for their preparation, and uses therefor
    申请人:The Rockefeller University
    公开号:US05874587A1
    公开(公告)日:1999-02-23
    Novel imidazolium compounds of the formula ##STR1## wherein A represents the atomic group necessary to form a heteroaromatic ring, which may be optionally substituted by one or more R substituents selected from the group consisting of aryl, heteroaryl, lower alkyl, hydroxy, halide, or carboxy substitutents; B is an optional substituent which represents the atomic group necessary to form a heteroaromatic ring or a double or triple carbon-nitrogen bond, which may optionally be substituted by one or more R' substituents selected from the group consisting of aryl, heteroaryl, lower alkyl, hydroxy, halide, or carboxy substitutents; C is an optional substituent which represents the atomic group necessary to form an aromatic or heteroaromatic ring, which may optionally be substituted by one or more R"" substituents selected from the group consisting of aryl, heteroaryl, lower alkyl, hydroxy, halide, or carboxy substituents; R" and R'" are each independently a lower alkyl or aryl group, or together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 5 to 7 members, which may optionally contain a sulfur, oxygen, silicon, selenium or an additional nitrogen atom; and X is an anion; are useful in a variety of industrial and medical applications.
    式子为##STR1##的新型咪唑化合物,其中A代表形成杂环芳香环所需的原子基团,该基团可以选择性地被一个或多个R取代,所述R取代基团选自芳基、杂芳基、较低的烷基、羟基、卤素或羧基取代基团;B是一个可选取代基团,代表形成杂环芳香环或双或三重碳氮键所需的原子基团,该基团可以选择性地被一个或多个R' 取代,所述R' 取代基团选自芳基、杂芳基、较低的烷基、羟基、卤素或羧基取代基团;C是一个可选取代基团,代表形成芳香或杂芳香环所需的原子基团,该基团可以选择性地被一个或多个R"" 取代,所述R"" 取代基团选自芳基、杂芳基、较低的烷基、羟基、卤素或羧基取代基团;R"和R'"各自独立地是较低的烷基或芳基基团,或者与它们所连接的氮原子一起形成一个含有5到7个成员的杂环,该杂环可以选择性地包含硫、氧、硅、硒或另一个氮原子;X是一个阴离子。这些化合物在各种工业和医疗应用中有用。
  • US5874587A
    申请人:——
    公开号:US5874587A
    公开(公告)日:1999-02-23
  • US6087510A
    申请人:——
    公开号:US6087510A
    公开(公告)日:2000-07-11
  • US6187928B1
    申请人:——
    公开号:US6187928B1
    公开(公告)日:2001-02-13
查看更多

同类化合物

氨甲酸,(5-氨基-2,3-二苯基吡啶并[3,4-b]吡嗪-7-基)-,乙基酯 咪唑并[1,5-a]吡啶并[3,2-e]吡嗪-6(5H)-酮 咪唑并[1,5-A]吡啶并[2,3-E]吡嗪-4(5H)-酮 咪唑并[1,2-a]吡啶并[3,2-E]吡嗪-6-醇 咪唑并[1,2-a]吡啶并[2,3-E]吡嗪-4(5H)-酮 吡啶并[3,4-b]吡嗪-7-胺 吡啶并[3,4-b]吡嗪-3(4h)-酮 吡啶并[3,4-b]吡嗪-2,3(1H,4H)-二酮 吡啶并[2,3-b]吡嗪-7-基硼酸频那醇酯 吡啶并[2,3-b]吡嗪-6(5H)-酮 吡啶并[2,3-b]吡嗪-2-羧酸 吡啶并[2,3-b]吡嗪-2(1h)-酮 吡啶并[2,3-b]吡嗪-2(1H)-酮,3,6-二甲基-(9CI) 吡啶并[2,3-B]吡嗪-8-甲醛 吡啶并[2,3-B]吡嗪-6-胺 吡啶并[2,3-B]吡嗪-6-羧酸 乙基[3-(4-氯苯基)-8-{[5-(二乙胺基)戊烷-2-基]氨基}吡啶并[2,3-b]吡嗪-6-基]氨基甲酸酯 乙基4-甲基-3-羰基-3,4-二氢吡啶并[2,3-b]吡嗪-2-羧酸酯 乙基(8-amino-2-{[methyl(phenyl)amino]methyl}pyrido[2,3-b]pyrazin-6-yl)氨基甲酸酯 N-乙基-N'-[3-[(4-甲基苯基)氨基]吡啶并[2,3-B]吡嗪-6-基]脲 N-[3-(4-羟基苯基)吡啶并[2,3-b]吡嗪-6-基]-N'-2-丙烯-1-基硫脲 8-甲基吡啶并[2,3-b]吡嗪 8-溴吡啶并[3,4-b]吡嗪 8-氯吡喃并[3,4-b]吡嗪 7-碘-吡啶并[2,3-b]吡嗪 7-硝基吡啶并[2,3-b]吡嗪 7-溴吡啶并[2,3-b]吡嗪 7-溴吡啶并[2,3-B]吡嗪-2,3(1H,4H)-二酮 7-溴-8-甲基吡啶并[2,3-B〕吡嗪 7-溴-6-甲基吡啶并[2,3-B]吡嗪 7-溴-2-甲基吡啶并[2,3-B]吡嗪 7-溴-2,3-二甲基吡啶并[2,3-b]吡嗪 7-氯吡啶并[3,4-b]吡嗪 7-氯-1,4-二氢吡啶并[2,3-B]吡嗪-2,3-二酮 7-氯-1,4-二氢-1-(2-丙氧乙基)-吡啶并[3,4-b]吡嗪-2,3-二酮 7-氨基吡啶并[2,3-B]吡嗪 6-肼基-3-苯基吡啶并[2,3-b]吡嗪-2-醇 6-甲氧基吡啶并[2,3-b]吡嗪-3(4h)-酮 6-溴吡啶并[2,3-B]吡嗪 6-氯咪唑并[1,5-a]吡啶并[3,2-e]吡嗪 6-氯吡啶并[3,2-B]吡嗪 6-氯吡啶并[2,3-b]吡嗪-2(1H)-酮 6-氯吡啶并[2,3-B]吡嗪-3(4H)-酮 6-氨基-3-羟基-吡啶并[2,3-B]吡嗪-2-羧酸 5-氯-吡啶[3,4-B]吡嗪 5,8-二氢-环丁[b]吡啶并[3,4-e]吡嗪-6,7-二酮 5,8-二氢-环丁[b]吡啶并[2,3-e]吡嗪-6,7-二酮 5,7-二氯吡啶并[4,3-b]吡嗪 4H-吡啶并[2,3-b]吡嗪-3-酮 4-(2,2-二甲基-1,3-二噁烷-5-基)-6-甲氧基吡啶并[2,3-B]吡嗪-3(4H)-酮